Skip to contentX
Xenon Pharmaceuticals Inc.
X
XENEXenon Pharmaceuticals Inc. Q1 2025 · 10-Q
Revenue$7.50M$7.50M— vs Q1 2024 Net Income-$65.05M-$65.05MN/M vs Q1 2024 EPS Diluted-$0.83-$0.83N/M vs Q1 2024 Operating Income-$72,738,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
Free Cash Flowderived-$61,695,000N/M Margins · derivedOperating margin-969.8%
Net margin-867.3%
ended Mar 31, 2025 · filed May 12, 2025 · 42 d after period end